ArticleAnnals of Indian Academy of Neurology2025
Efficacy of Subcutaneous and Intravenous Immunoglobulin in Patients with Multifocal Motor Neuropathy: A Systematic Review and Meta-analysis.
Article in Annals of Indian Academy of Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMultifocal motor neuropathy (MMN) is an uncommon chronic autoimmune disorder in adults. Several randomized and non-randomized studies with small sample sizes have shown promising results with subcutaneous immunoglobulin (SCIg) in MMN patients who have a stable disease course with intravenous immunoglobulin (IVIg). This systematic review aimed to compare the efficacy of SCIg and IVIg treatment in MMN patients in terms of changes in muscle power, grip strength, motor function, disability, quality of life, as well as adverse effects.
methodsRandom- or fixed-effect model was used, as appropriate, to determine the pooled weighted estimates for outcome variables, depending on the degree of heterogeneity. A total of 11 publications from nine studies (110 patients, mean age 54.3 ± 3.4 years, 57% males, duration of illness 9.7 ± 2.4 years) were included in the review.
resultsChanges in the Medical Research Council sum score (MRC-SS), grip strength, dexterity, and disability due to neuropathy following IVIg and SCIg administration were comparable ( P = 0.30, I ² = 9%; P = 0.51, I ² = 0%; P = 0.45, I ² = 0%; and P = 0.57, I ² = 0%, respectively). Changes in health-related quality of life were numerically better with SCIg, although the difference did not reach statistical significance ( P = 0.17, I ² = 72%,). Over the long term, there was a trend toward fewer disease fluctuations compared to IVIg ( P = 0.43), and the efficacy comparable to IVIg was maintained in terms of muscle strength, disability, and quality of life parameters ( P = 0.83, 0.85, and 0.59, respectively). The incidence of moderate to severe systemic adverse effects was significantly lower with SCIg infusion compared to previous years when patients received IVIg ( P = 0.03).
conclusionsSCIg can be considered an acceptable alternative to IVIg in patients with MMN, with a better safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.